A blood-thinner that entered the U.S. market less than four years ago has now been named in over 2,000 federal Pradaxa lawsuit filings, according to its manufacturer.

A February 13th report from Reuters.com indicates that Boehringer-Ingelheim has told readers of the German newspaper, Handelsblatt, about its involvement in pending Pradaxa bleeding claims. Among other things, the company said that benefits of the blood-thinning medication should be weighed against its side effects, which may include the life-threatening episodes of internal bleeding alleged in thousands of product liability lawsuits. These cases, which have been filed by alleged Pradaxa bleeding victims and their families, are currently pending in the U.S. District Court, Southern District of Illinois.

“We are certain that we can show in the legal cases that we have worked very carefully and responsibly in research, development and marketing of Pradaxa,” Boehringer told the publication.

According to Reuters, sales of Pradaxa weighed in at 1.1 billion euros in 2012. The blood-thinner competes with Xarelto, sold by Bayer and Johnson & Johnson, as well as Pfizer’s Eliquis.

Perhaps drawing the biggest comparison to Pradaxa though, is its predecessor, warfarin. A decades-old medication also used to reduce the risk of strokes and embolism in patients with non-vulvular atrial fibrillation, this drug has also been associated with episodes of internal bleeding that may be reversible with the administration of Vitamin K. With Pradaxa, lawsuits point out that there is no readily available antidote to stop episodes of internal bleeding once it begins, which can allegedly lead to death.

Pradaxa Internal Bleeding Docs Recently Unsealed in Federal Litigation

Court documents indicate that recent updates in the Southern District of Illinois may impact drug-related claims against Boehringer. At the end of January, a series of e-mails, memos and internal presentations related to the company’s internal Pradaxa research were unsealed in the Southern District of Illinois, revealing that some marketing claims about the blood-thinner may not stand.

In particular, a February 5th report from the New York Times indicates that one particular research paper may raise questions about Boehringer’s assertions that Pradaxa users are not required to undergo routine blood testing to monitor its effectiveness.

The company study found that some users of the drug were given too little, and some were given too much. This heightened their risk for episodes of Pradaxa bleeding, according to the Times.

Filing a Pradaxa Lawsuit

Contact our Firm today for more information about Pradaxa bleeding injuries, and whether you may be eligible to file a lawsuit against Boehringer-Ingelheim. Call us today at (877) 779-1414.

Published February 14, 2014 by